RIP MTD: FDA to require sponsors to determine optimal dosage before initiating pivotal trials in cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA officials said drug sponsors will soon be required to conduct randomized studies to determine optimal dosages of cancer drugs before proceeding to testing safety and efficacy in pivotal trials.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Editor & Publisher
Table of Contents


Editor & Publisher